Japan
Osaka City General Hospital
locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel
epidermal growth factor receptor mutation (EGFR), EGFR-TKI, and adjuvant therapy
high-grade neuroendocrine carcinoma, Small-cell lung cancer, large-cell neuroendocrine carcinoma, cisplatin, irinotecan, etoposide, Relative dose intensity